- Home
- FABC vs TOVX Comparison
FABC vs TOVX Comparison
Compare FABC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FABC | TOVX |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | United States |
| Employees | 108 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 11.1M |
| IPO Year | 1999 | 2012 |
Fundamental Metrics
Financial Performance| Metric | FABC | TOVX |
|---|---|---|
| Price | $1.65 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 95.0K | ★ 1.0M |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,579,745.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $0.14 |
| 52 Week High | $4.57 | $0.49 |
Technical Indicators
Market Signals| Indicator | FABC | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 29.53 |
| Support Level | $1.43 | $0.14 |
| Resistance Level | $2.43 | $0.25 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 24.42 | 17.68 |
Price Performance
Historical ComparisonAbout FABC Fabric.AI Inc. Common Stock
Fabric.AI Inc is an infrastructure company building a suite of fabless semiconductor technologies to power AI factories - smart data centers optimized for producing intelligence at scale. The company's innovations include MicroLED-based optical interconnects and other system-critical technologies that enable faster, more efficient, and more scalable AI workloads. Its mission is to transform data centers into unified production systems for artificial intelligence.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.